Cargando…

Thromboembolic, cardiovascular and overall mortality risks of aromatase inhibitors, compared with tamoxifen treatment: an outpatient-register-based retrospective cohort study

BACKGROUND: Tamoxifen (TAM) and aromatase inhibitor (AI) therapies have been associated with increased risk of thromboembolic and cardiovascular events, respectively, in addition to other side effects. This study analysed the risk of these events and the overall survival (OS) benefit in breast cance...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pineda-Moncusí, Marta, Garcia-Giralt, Natalia, Diez-Perez, Adolfo, Tusquets, Ignasi, Servitja, Sonia, Albanell, Joan, Prieto-Alhambra, Daniel, Nogués, Xavier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097872/ https://www.ncbi.nlm.nih.gov/pubmed/32231712 http://dx.doi.org/10.1177/1758835920909660

Ejemplares similares

Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy
por: Muntasell, Aura, et al.
Publicado: (2017)

Precautions for Patients Taking Tamoxifen or Aromatase Inhibitors
por: Heery, Mary
Publicado: (2023)

Cutaneous sarcoidosis possibly associated with aromatase inhibitors and tamoxifen
por: Sawada, Tomoya, et al.
Publicado: (2023)

Effectiveness of aromatase inhibitors and tamoxifen in reducing subsequent breast cancer
por: Haque, Reina, et al.
Publicado: (2012)

Deficiency in p53 is required for doxorubicin induced transcriptional activation of NF-κB target genes in human breast cancer
por: Dalmases, Alba, et al.
Publicado: (2013)

Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen?
por: Cuzick, J, et al.
Publicado: (2006)

Adjuvant Aromatase Inhibitors or Tamoxifen Following Chemotherapy for Perimenopausal Breast Cancer Patients
por: Dackus, Gwen M H E, et al.
Publicado: (2021)

Differential impact of tamoxifen and aromatase inhibitors on thrombin generation: the prospective HEMOBREAST cohort
por: Blondon, Marc, et al.
Publicado: (2022)

Functional Assessment of Coding and Regulatory Variants From the DKK1 Locus
por: Martínez‐Gil, Núria, et al.
Publicado: (2020)

Non-canonical NF-κB pathway activation predicts outcome in borderline oestrogen receptor positive breast carcinoma
por: Rojo, Federico, et al.
Publicado: (2016)

Stick or switch? Audit of the use of switch therapy from tamoxifen to an aromatase inhibitor in breast cancer
por: Weeraman, S, et al.
Publicado: (2010)

Use of tamoxifen and aromatase inhibitors in a large population-based cohort of women with breast cancer
por: Huiart, L, et al.
Publicado: (2011)

Persistence with tamoxifen and aromatase inhibitors in Germany: a retrospective cohort study with 284,383 patients
por: Gremke, Niklas, et al.
Publicado: (2022)

Dietary Supplement Use and Interactions with Tamoxifen and Aromatase Inhibitors in Breast Cancer Survivors Enrolled in Lifestyle Interventions
por: Harrigan, Maura, et al.
Publicado: (2021)

Fracture risk in type 2 diabetic patients: A clinical prediction tool based on a large population-based cohort
por: Martínez-Laguna, Daniel, et al.
Publicado: (2018)

Estimating the Incidence and Key Risk Factors of Cardiovascular Disease in Patients at High Risk of Imminent Fracture Using Routinely Collected Real‐World Data From the UK
por: Pineda‐Moncusí, Marta, et al.
Publicado: (2022)

Incidence of Comorbidities in Women with Breast Cancer Treated with Tamoxifen or an Aromatase Inhibitor: An Australian Population-Based Cohort Study
por: Ng, Huah Shin, et al.
Publicado: (2018)

Plasma levels of Semaphorin 4D are decreased by adjuvant tamoxifen but not aromatase inhibitor therapy in breast cancer patients
por: Göbel, Andy, et al.
Publicado: (2019)

Tamoxifen or aromatase inhibitors with ovarian function suppression in pre-menopausal stage I-III lobular breast cancer
por: Record, Helena, et al.
Publicado: (2023)

“Burden of osteoporotic fractures in primary health care in Catalonia (Spain): a population-based study”
por: Pagès-Castellà, Aina, et al.
Publicado: (2012)

Insulin use and Excess Fracture Risk in Patients with Type 2 Diabetes: A Propensity-Matched cohort analysis
por: Losada-Grande, Eladio, et al.
Publicado: (2017)

Pro-osteoporotic miR-320a impairs osteoblast function and induces oxidative stress
por: De-Ugarte, Laura, et al.
Publicado: (2018)

Haemostatic changes and thromboembolic risk during tamoxifen therapy in normal women.
por: Jones, A. L., et al.
Publicado: (1992)

Effects of tamoxifen and aromatase inhibitors on the risk of acute coronary syndrome in elderly breast cancer patients: An analysis of nationwide data
por: Choi, Sung Hyouk, et al.
Publicado: (2020)

Hemorrhage Risk Among Patients With Breast Cancer Receiving Concurrent Direct Oral Anticoagulants With Tamoxifen vs Aromatase Inhibitors
por: Wang, Tzu-Fei, et al.
Publicado: (2022)

Mortality, Falls, and Fracture Risk Are Positively Associated With Frailty: A SIDIAP Cohort Study of 890 000 Patients
por: Middleton, Robert, et al.
Publicado: (2021)

Acquired Bilateral Nevoid Telangiectasia Induced by Tamoxifen
por: Navarro-Navarro, Irene, et al.
Publicado: (2023)

Overall and abdominal obesity in relation to venous thromboembolism
por: Yuan, Shuai, et al.
Publicado: (2020)

Tamoxifen treatment for male breast cancer and risk of thromboembolism: prospective cohort analysis
por: Eggemann, Holm, et al.
Publicado: (2019)

Aortic Thrombus Extending to Left Subclavian in a Patient With Diffuse Venous Thromboembolism on Aromatase Inhibitor Therapy
por: Alsamman, Mrhaf, et al.
Publicado: (2021)

Is tamoxifen associated with an increased risk for thromboembolic complications in patients undergoing microvascular breast reconstruction?
por: Jokuszies, Andreas, et al.
Publicado: (2013)

A Systematic Review and Methodological Evaluation of Published Cost-Effectiveness Analyses of Aromatase Inhibitors versus Tamoxifen in Early Stage Breast Cancer
por: John-Baptiste, Ava A., et al.
Publicado: (2013)

Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations
por: Tamborero, David, et al.
Publicado: (2018)

Cost-effectiveness of Tamoxifen, Aromatase Inhibitor, and Switch Therapy (Adjuvant Endocrine Therapy) for Breast Cancer in Hormone Receptor Positive Postmenopausal Women in India
por: Butani, Dimple, et al.
Publicado: (2021)

Long-Term Effect of Aromatase Inhibition in Aromatase Excess Syndrome
por: Binder, Gerhard, et al.
Publicado: (2021)

Letrozole efficacy is related to human aromatase CYP19 single nucleotide polymorphisms (SNPs) in metastatic breast cancer
por: Colomer, R, et al.
Publicado: (2005)

The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma
por: McClay, E F, et al.
Publicado: (2000)

Risk of myocardial infarction and overall mortality in survivors of venous thromboembolism
por: Huerta, Consuelo, et al.
Publicado: (2008)

Genetic risk and incident venous thromboembolism in middle‐aged and older adults following COVID‐19 vaccination
por: Xie, Junqing, et al.
Publicado: (2022)

Clinical and Genetic Risk Factors for Acute Incident Venous Thromboembolism in Ambulatory Patients With COVID-19
por: Xie, JunQing, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5fgu7ogodjjso2iq0a722o6m99